Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | 0.00% | +8.97% | -39.12% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Neutral | Neutral |
Resistance | 2.610 | 4.490 | 4.320 |
Spread/Res. | -4.60% | -44.54% | -42.36% |
Spread/Supp. | +8.97% | +26.40% | +15.81% |
Support | 2.285 | 1.970 | 2.150 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- ORGO Stock
- Charts Organogenesis Holdings Inc.